Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Solid Tumor 1Locally Advanced Unresectable Gastric Cancer 1Digestive System Neoplasms 1Cholangiocarcinoma 1Carcinoma 1Advanced Non-Small Cell Lung Cancer 1Advanced Non Small Cell Lung Cancer 1

Interventions

Injections 4apatinib 3Cisplatin 3Capecitabine 3toripalimab 2alpha-Synuclein 2Oxaliplatin 2Gemcitabine 2Drug Therapy 2Docetaxel 2trametinib 1tislelizumab 1tesetaxel 1surufatinib 1spartalizumab 1pyrotinib 1pemigatinib 1pembrolizumab 1nimotuzumab 1mogamulizumab 1irinotecan sucrosofate 1fludarabine 1famitinib 1dalpiciclib 1camrelizumab 1YM753 compound 1Vemurafenib 1Taxes 1SHR-1701 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Solid Tumor × pemigatinib × Clear all
NCT06022289 2023-09-01

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Tianjin Medical University Second Hospital

Phase 2 Unknown
20 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡